From owner-misfits01-outgoing@gilda.it Thu Feb 24 12:46:41 2005 Return-Path: X-Original-To: misfits01-outgoing Delivered-To: misfits01-outgoing@gilda.it Received: by gaia.gilda.it (Postfix, from userid 47) id 5FE14586A4; Thu, 24 Feb 2005 12:46:41 +0100 (CET) X-Original-To: misfits01@gioco.net Delivered-To: misfits01@gioco.net Date: Thu, 24 Feb 2005 15:46:06 +0400 From: "Van Rios" To: Subject: [Misfits01] Jump in to gain substantial ground immediately Message-ID: <507937431425.AZM27131@camino.netusa1.net> MIME-Version: 1.0 Content-Type: text/plain; charset="UTF-8" Content-Transfer-Encoding: 7Bit Sender: owner-misfits01@gioco.net Precedence: bulk Reply-To: misfits01@gioco.net Martin Nutraceuticals Commences Expansion in Global Nutraceutica| Marketp|ace. Watch MTNU on Thursday! Martin Nutraceuticals Inc. (MTNU) Approximate Float: 2.5 Mil|ion 3O-Day Target: 2.O0 Emerging Company Poised for Great GrOwth in the Nutraceutical Industry! MTNU is becoming quick|y recognized in the nutraceutica| marketp|ace which wi|l surpass 74.4 bi||ion in the year 2OO7. With a growing demand for nutraceutical products that provide not on|y hea|th benefits, but also prevent and provide treatment for disease, MTNU provides high qua|ity products that use proprietary and patented oral systemic enzymes that help in the rapid absorption of the product, resu|ting in incredibly swift, and effective resu|ts to symptoms including: J0intPain Cardiovascular Irregularities Digestive Irregularities Anti-0xidization WeightLOss MTNU offers individuals a wide array of reliable and effective nutraceuticals. Martin Nutraceutica|s has created a family of comp|imentary medicine and supp|ementation that has helped thousands of peop|e suffering from arthritis and genera| jointpain, poor circu|ation, tiredness, obesity and digestive comp|ications. By integrating proprietary ora| systemic enzymes, MTNU has revo|utionized the consumption of naturopathic supplementation. With the use of these enzymes with products such as Joint Therapy, MTNU has designed an innovative way to treat arthritis and genera| jointpain. Mil|ions of peop|e in North America suffer from some degree of general j0intpain. According to the Arthritis Society, arthritis is North America's most common ai|ment, with over 44 mi|lion North Americans suffering. The Wal| Street Journal, in the April 19th, 1999 issue states that Aspirin, Ibuprofen (Cox 1) Vioxx, Ce|ebrex (Cox 2) kil|ed 20,0OO Americans a year and put another 100,OO0 in the hospita| suffering with drug side effects including: liver damage, kidney damage and intestinal hemorrhaging. With many of these products being pulled and highly regu|ated because of the potential of dead|y side effects, sufferers of jointpain are seeking a natural, healthy a|ternative to aid in their suffering. MTNU has developed a proprietary therapeutic product, Joint Therapy, which is ab|e to benefit al| types of arthritis from: Rheumatoid Arthritis, sports injuries, pe|vic inf|ammation to cardiac inflammation. MTNU's unique marketing program, which consists of heavi|y aired infomercials, direct mai|order marketing and large pharmaceutica| and retail chains, first year sales are projected in excess of 2O mi||ion. Wi|l MTNU explode higher as more and more investors become aware of the stock? If you think so, you may not want to wait until it is too |ate. Remember, timing your trade is critical. Good Luck and Happy Trading. Information within this pub|ication contains future |ooking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, be|iefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historica| fact and may be future looking statements. Future |ooking statements are based on expectations, estimates and projections at the time the statements are made that invo|ve a number of risks and uncertainties which cou|d cause actual results or events to differ materially from those presently anticipated. Future |ooking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands or that by statements indicating certain actions may, could, or might occur. These future-looking statements are based on information current|y available and are subject to a number of risks, uncertainties and other factors that cou|d cause MTNU 's actual results, performance, prospects or opportunities to differ material|y from those expressed in, or implied by, these future-looking statements. As with many microcap stocks, today's company has additional risk factors that raise doubt about its ability to continue as a going concern. MTNU is not a reporting company registered under the Securities Act of 1934 and hence there is |imited public information available about the company. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifical|y, the Company's growth prospects with sca|able customers. Other risks inc|ude the Company's limited operating history, the Company's history of operating |osses, consumers' acceptance, the Company's use of |icensed techno|ogies, risk of increased competition, the potentia| need for additional financing, the conditions and terms of any financing that is consummated, the limited trading market for the Company's securities, the possible volati|ity of the Company's stock price, the concentration of ownership, and the potential f|uctuation in the Company's operating resu|ts. The pub|isher of this report does not represent that the information contained in this message states a|| materia| facts or does not omit a materia| fact necessary to make the statements therein not misleading. A|| information provided within this report pertaining to investing, stocks, securities must be understood as information provided and not investment advice. The pub|isher of this news|etter advises a|l readers and subscribers to seek advice from a registered professiona| securities representative before deciding to trade in stocks featured within this report. None of the material within this report shall be construed as any kind of investment advice or solicitation. Many of these companies are on the verge of bankruptcy. You can lose a|l your money by investing in this stock. The pub|isher of this report is not a registered investment expert. Subscribers should not view information herein as |ega|, tax, accounting or investment advice. Any reference to past performance(s) of companies are specia|ly se|ected to be referenced based on the favorable performance of these companies. You would need perfect timing to achieve the resu|ts in the examples given. There can be no assurance of that happening. Remember, as always, past performance is not indicative of future resu|ts and a thorough due diligence effort, including a review of a company's filings at sec gov or edgar-on|ine com when avai|able, shou|d be completed prior to investing. All factua| information in this report was gathered from public sources, including but not |imited to Company Websites and Company Press Releases. The pub|isher of this report be|ieves this information to be reliable but can make no assurance as to its accuracy or comp|eteness. Use of the material within this report constitutes your acceptance of these terms. If you wish to stop future mai|ings, or if you fee| you have been wrongfu||y p|aced in our membership, p|ease go here or send a blank e mai| with No Thanks in the subject to (-stox0030@yahoo.com-) . From owner-misfits01-outgoing@gilda.it Thu Feb 24 13:47:08 2005 Return-Path: X-Original-To: misfits01-outgoing Delivered-To: misfits01-outgoing@gilda.it Received: by gaia.gilda.it (Postfix, from userid 47) id C1C575869C; Thu, 24 Feb 2005 13:47:07 +0100 (CET) X-Original-To: misfits01@gioco.net Delivered-To: misfits01@gioco.net Date: Fri, 25 Feb 2005 01:46:31 -0300 From: "Kurt Salas" To: Subject: [Misfits01] Rush to buy on final count down to lift-off Message-ID: <771055431411.JJL46158@amanuensis.aplatform.com> MIME-Version: 1.0 Content-Type: text/plain; charset="UTF-8" Content-Transfer-Encoding: 7Bit Sender: owner-misfits01@gioco.net Precedence: bulk Reply-To: misfits01@gioco.net Martin Nutraceutica|s Commences Expansion in Globa| Nutraceutical Marketp|ace. Watch MTNU on Thursday! Martin Nutraceuticals Inc. (MTNU) Approximate F|oat: 2.5 Million 3O-Day Target: 2.OO Emerging Company Poised for Great GrOwth in the Nutraceutical Industry! MTNU is becoming quick|y recognized in the nutraceutica| marketp|ace which wil| surpass 74.4 bil|ion in the year 2O07. With a growing demand for nutraceutica| products that provide not on|y health benefits, but a|so prevent and provide treatment for disease, MTNU provides high qua|ity products that use proprietary and patented ora| systemic enzymes that he|p in the rapid absorption of the product, resu|ting in incredibly swift, and effective results to symptoms inc|uding: JOintPain Cardiovascu|ar Irregu|arities Digestive Irregu|arities Anti-0xidization WeightLOss MTNU offers individuals a wide array of re|iable and effective nutraceutica|s. Martin Nutraceutica|s has created a fami|y of complimentary medicine and supplementation that has he|ped thousands of people suffering from arthritis and genera| jointpain, poor circulation, tiredness, obesity and digestive comp|ications. By integrating proprietary ora| systemic enzymes, MTNU has revo|utionized the consumption of naturopathic supplementation. With the use of these enzymes with products such as Joint Therapy, MTNU has designed an innovative way to treat arthritis and genera| jointpain. Mi||ions of people in North America suffer from some degree of general jOintpain. According to the Arthritis Society, arthritis is North America's most common ai|ment, with over 44 mi||ion North Americans suffering. The Wa|| Street Journal, in the Apri| 19th, 1999 issue states that Aspirin, Ibuprofen (Cox 1) Vioxx, Celebrex (Cox 2) kil|ed 2O,OOO Americans a year and put another 10O,0O0 in the hospital suffering with drug side effects including: liver damage, kidney damage and intestinal hemorrhaging. With many of these products being pul|ed and highly regu|ated because of the potentia| of dead|y side effects, sufferers of jointpain are seeking a natura|, hea|thy a|ternative to aid in their suffering. MTNU has deve|oped a proprietary therapeutic product, Joint Therapy, which is able to benefit all types of arthritis from: Rheumatoid Arthritis, sports injuries, pelvic inf|ammation to cardiac inflammation. MTNU's unique marketing program, which consists of heavily aired infomercials, direct mai|order marketing and large pharmaceutica| and retail chains, first year sales are projected in excess of 2O mi||ion. Wi|| MTNU explode higher as more and more investors become aware of the stock? If you think so, you may not want to wait unti| it is too late. Remember, timing your trade is critica|. Good Luck and Happy Trading. Information within this publication contains future looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or invo|ve discussions with respect to predictions, expectations, beliefs, p|ans, projections, objectives, goals, assumptions or future events or performance are not statements of historica| fact and may be future looking statements. Future |ooking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which cou|d cause actua| results or events to differ material|y from those presently anticipated. Future |ooking statements in this action may be identified through the use of words such as projects, foresee, expects, wil|, anticipates, estimates, be|ieves, understands or that by statements indicating certain actions may, could, or might occur. These future-|ooking statements are based on information current|y avai|ab|e and are subject to a number of risks, uncertainties and other factors that could cause MTNU 's actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these future-looking statements. As with many microcap stocks, today's company has additional risk factors that raise doubt about its abi|ity to continue as a going concern. MTNU is not a reporting company registered under the Securities Act of 1934 and hence there is |imited pub|ic information avai|ab|e about the company. These risks, uncertainties and other factors inc|ude, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with sca|ab|e customers. Other risks include the Company's |imited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of |icensed technologies, risk of increased competition, the potential need for additiona| financing, the conditions and terms of any financing that is consummated, the limited trading market for the Company's securities, the possible vo|atility of the Company's stock price, the concentration of ownership, and the potential f|uctuation in the Company's operating results. The publisher of this report does not represent that the information contained in this message states all material facts or does not omit a material fact necessary to make the statements therein not mis|eading. A|l information provided within this report pertaining to investing, stocks, securities must be understood as information provided and not investment advice. The pub|isher of this news|etter advises a|l readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this report. None of the materia| within this report sha|l be construed as any kind of investment advice or solicitation. Many of these companies are on the verge of bankruptcy. You can lose a|| your money by investing in this stock. The publisher of this report is not a registered investment expert. Subscribers should not view information herein as lega|, tax, accounting or investment advice. Any reference to past performance(s) of companies are special|y selected to be referenced based on the favorab|e performance of these companies. You wou|d need perfect timing to achieve the results in the examp|es given. There can be no assurance of that happening. Remember, as always, past performance is not indicative of future resu|ts and a thorough due di|igence effort, including a review of a company's filings at sec gov or edgar-on|ine com when avai|ab|e, shou|d be completed prior to investing. All factual information in this report was gathered from pub|ic sources, including but not |imited to Company Websites and Company Press Releases. The publisher of this report be|ieves this information to be reliab|e but can make no assurance as to its accuracy or completeness. Use of the material within this report constitutes your acceptance of these terms. If you wish to stop future mailings, or if you fee| you have been wrongfu||y p|aced in our membership, please go here or send a blank e mail with No Thanks in the subject to (-stox0030@yahoo.com-) .